Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Related Posts
Macdonald P, Nair G, Wattrus C, Mullick S, Pleaner M, Rousseau E, Subedar H, Joseph-Davey D, Hugo J, Delany-Moretlwe S, Bekker LG. Southern African HIV[...]
Joseph Davey D, Fynn L, Rousseau E, Macdonald P, Leonard B, Lebelo K, Kolisa A, Little F, Bekker LG. Evaluation of point-of-care diagnostics for sexually[...]
Joshi A, Kamaraj M, Moghimi N, Heidari H, Aghamaleky-Sarvestany A, Rahim CSA, Rodriguez-Sanchez DN, Hu C, Aravindan S, Nair DSR, Huang NF, Thomas BB, Sareen[...]